- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
- 个人中心
- 退出登录
浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Clinical observation of esmolol for acute anterior ST-segment elevation myocardial infarction in patients undergoing PCI
- ZHONGGUO YAOFANG Vol. 35, Issue 23, Pages: 2903-2907(2024)
- 作者机构：
1.新乡市中心医院冠心病监护病房/新乡市重症医学与药理研究重点实验室/新乡市体外生命支持工程技术研究中心，河南 新乡 453000
2.新乡市中心医院心内科，河南 新乡 453000
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.23.11
CLC： R972;R542.2Published：15 December 2024，
Received：03 July 2024，
Revised：07 November 2024，
- 稿件说明：
移动端阅览
杨树涵,周姝,任彦锋等.艾司洛尔用于急性前壁ST段抬高型心肌梗死PCI后患者的临床观察 Δ[J].中国药房,2024,35(23):2903-2907.
YANG Shuhan,ZHOU Shu,REN Yanfeng,et al.Clinical observation of esmolol for acute anterior ST-segment elevation myocardial infarction in patients undergoing PCI[J].ZHONGGUO YAOFANG,2024,35(23):2903-2907.
杨树涵,周姝,任彦锋等.艾司洛尔用于急性前壁ST段抬高型心肌梗死PCI后患者的临床观察 Δ[J].中国药房,2024,35(23):2903-2907. DOI： 10.6039/j.issn.1001-0408.2024.23.11.
YANG Shuhan,ZHOU Shu,REN Yanfeng,et al.Clinical observation of esmolol for acute anterior ST-segment elevation myocardial infarction in patients undergoing PCI[J].ZHONGGUO YAOFANG,2024,35(23):2903-2907. DOI： 10.6039/j.issn.1001-0408.2024.23.11.
摘要
目的
2
探究艾司洛尔对急性前壁ST段抬高型心肌梗死经皮冠脉介入术（PCI）患者心功能、炎症因子和血清中微小RNA（miR）-29a、miR-129-5p的影响，并评价其安全性。
方法
2
选取2021年4月至2023年6月于我院行PCI治疗的急性前壁ST段抬高型心肌梗死患者120例，按随机数字表法分为对照组（60例）和研究组（60例）。对照组患者予以常规治疗，研究组患者在对照组的基础上给予盐酸艾司洛尔注射液。两组均连续治疗1周。观察两组患者的心功能指标（左室射血分数、左室收缩末期容积指数、左室舒张末期内径、高峰射血分数、心输出量）、炎症因子（C反应蛋白、髓过氧化物酶、白细胞介素6、脑利尿钠肽、同型半胱氨酸）、心肌酶指标（肌酸激酶同工酶MB、
β
2
-微球蛋白、心肌肌钙蛋白Ⅰ）水平和血清中miR-29a、miR-129-5p表达量，并记录不良反应发生情况。
结果
2
治疗1周后，两组患者的左室射血分数、高峰射血分数、心输出量和血清中miR-129-5p表达量均显著高于同组治疗前（
P
＜0.05），左室收缩末期容积指数、左室舒张末期内径、炎症因子水平、心肌酶指标水平和血清中miR-29a表达量均显著低于同组治疗前（
P
＜0.05），且研究组显著优于对照组（除肌酸激酶同工酶MB水平）（
P
＜0.05）。两组患者的症状性低血压、症状性心动过缓、心源性休克、心律失常发生率比较，差异均无统计学意义（
P
＞0.05）。
结论
2
艾司洛尔能改善急性前壁ST段抬高型心肌梗死患者的心功能，降低炎症因子水平，减少心肌损伤，调节血清中miR-29a、miR-129-5p表达，且安全性较好。
Abstract
OBJECTIVE
2
To explore the effects of esmolol on cardiac function， inflammatory factors and serum microRNA （miR）-29a and miR-129-5p in patients with acute anterior ST-segment elevation myocardial infarction after percutaneous coronary intervention （PCI）.
METHODS
2
A total of 120 patients with acute anterior ST-segment elevation myocardial infarction undergoing PCI in our hospital from April 2021 to June 2023 were selected and divided into control group （60 cases） and study group （60 cases） according to the random number table method. The control group was given conventional treatment， and the study group was additionally given Esmolol hydrochloride injection based on the control group for one week. The levels of cardiac function indexes （left ventricular ejection fraction， left ventricular end-systolic volume index， left ventricular end-diastolic diameter， peak ejection fraction， cardiac output）， inflammatory factors （C-reactive protein， myeloperoxidase， interleukin-6， brain natriuretic peptide， homocysteine） myocardial enzyme indexes （creatine kinase isoenzyme，
β
2
-microglobulin， cardiac troponin
Ⅰ）， and serum expression of miR-29a and miR-129-5p were observed in two groups， and the occurrence of ADR was recorded.
RESULTS
2
After one week of treatment， left ventricular ejection fraction， peak ejection fraction， cardiac output， and the expression of miR-129-5p in two groups was significantly higher than before treatment （
P
＜0.05）， while left ventricular end-systolic volume index， left ventricular end-diastolic diameter， inflammatory factors and myocardial enzyme index levels， and the expression of miR-29a were significantly lower than before treatment （
P
＜0.05）. The study group was significantly better than the control group （except for the creatine kinase-MB） （
P
＜0.05）. There was no statistically significant difference in the incidence of symptomatic hypotension， symptomatic bradycardia， cardiogenic shock， and arrhythmia between two groups （
P
＞0.05）.
CONCLUSIONS
2
Esmolol can improve cardiac function， reduce inflammatory factors， lessen myocardial injury， and regulate serum expressions of miR-29a and miR-129-5p in patients with acute anterior ST-segment elevation myocardial infarction after PCI， with good safety.
关键词
艾司洛尔急性前壁ST段抬高型心肌梗死经皮冠脉介入术安全性炎症因子miR-29a
Keywords
acute anterior ST-segment elevation myocardial infarctionpercutaneous coronary interventionsafetyinflammatory factorsmiR-29a
references
KOFOED K F，ENGSTRØM T，SIGVARDSEN P E，et al. Prognostic value of coronary CT angiography in patients with non-ST-segment elevation acute coronary syndromes[J]. J Am Coll Cardiol，2021，77（8）：1044-1052.
刘丽丽，吴永霞，郭金成. 不同年龄段急性ST段抬高型心肌梗死患者急救医疗服务使用情况分析[J]. 中国急救医学，2022，42（8）：688-691.
LIU L L，WU Y X，GUO J C. Analysis of age differences in the use of emergency medical services among STEMI patients[J]. Chin J Crit Care Med，2022，42（8）：688-691.
姜子超，刘康，凌维维，等. 急性ST段抬高型心肌梗死直接PCI术后心肌内出血的危险因素分析[J]. 解放军医学杂志，2022，47（2）：171-177.
JIANG Z C，LIU K，LING W W，et al. Related factors of intramyocardial hemorrhage in patients with acute ST-segment elevation myocardial infarction after primary percutaneous coronary intervention[J]. Med J Chin People’s Liberation Army，2022，47（2）：171-177.
CHATTERJEE B，SARKAR M，BOSE S，et al. Micro- RNAs：key modulators of inflammation-associated diseases[J]. Semin Cell Dev Biol，2024，154（Pt C）：364-373.
BYRNE R A，ROSSELLO X，COUGHLAN J J，et al. 2023 ESC guidelines for the management of acute coronary syndromes[J]. Eur Heart J Acute Cardiovasc Care，2024，13（1）：55-161.
中华医学会心血管病学分会，中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南：2019[J]. 中华心血管病杂志，2019，47（10）：766-783.
Chinese Society of Cardiology of Chinese Medical Association，Editorial Board of Chinese Journal of Cardiology. 2019 Chinese Society of Cardiology（CSC）guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chin J Cardiol，2019，47（10）：766-783.
ALKAN A，HONCA M，ALKAN A，et al. The efficacy of esmolol，remifentanil and nitroglycerin in controlled hypotension for functional endoscopic sinus surgery[J]. Braz J Otorhinolaryngol，2021，87（3）：255-259.
LIANG Q H，LI L L，CHEN K R，et al. Effect of esmolol on clinical outcomes in critically ill patients：data from the MIMIC-Ⅳ database[J]. J Cardiovasc Pharmacol Ther，2023，28：10742484231185985.
CHEN Z M，PAN H C，CHEN Y P，et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction：randomised placebo-controlled trial[J]. Lancet，2005，366（9497）：1622-1632.
PODLESNIKAR T，PIZARRO G，FERNÁNDEZ-JIMÉNEZ R，et al. Five-year outcomes and prognostic value of feature-tracking cardiovascular magnetic resonance in patients receiving early prereperfusion meto- prolol in acute myocardial infarction[J]. Am J Cardiol，2020，133：39-47.
ROOLVINK V，IBÁÑEZ B，OTTERVANGER J P，et al. Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention[J]. J Am Coll Cardiol，2016，67（23）：2705-2715.
ER F，DAHLEM K M，NIA A M，et al. Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction：the BEtA-blocker therapy in acute myocardial infarction（BEAT-AMI）trial[J]. JACC Cardiovasc Interv，2016，9（3）：231-240.
LIU M X，YANG J，QIN Y，et al. Esmolol protects against LPS-induced cardiac injury via the AMPK/mTOR/ULK1 pathway in rat[J]. Shock，2023，59（3）：469-476.
黄剑，吴燕妮，朱静，等. 艾司洛尔在中青年急性前壁心肌梗死患者中的早期应用疗效分析[J]. 中华急诊医学杂志，2021，30（7）：816-820.
HUANG J，WU Y N，ZHU J，et al. Early application of esmolol in young and middle-aged patients with acute anterior myocardial infarction[J]. J Zhejiang Chin Med Univ，2021，30（7）：816-820.
华蓉，唐毅，李茜，等. 艾司洛尔治疗急性心肌梗死伴心房颤动合并急性心力衰竭患者1例[J]. 岭南心血管病杂志，2022，28（2）：180-181.
HUA R，TANG Y，LI Q，et al. Esmolol in the treatment of acute myocardial infarction with atrial fibrillation and acute heart failure：a case report[J]. South China J Cardiovasc Dis，2022，28（2）：180-181.
NIU X W，PU S S，LING C，et al. lncRNA Oip5-as1 attenuates myocardial ischaemia/reperfusion injury by sponging miR-29a to activate the SIRT1/AMPK/PGC1α pathway[J]. Cell Prolif，2020，53（6）：e12818.
MA R，CHEN X，MA Y，et al. MiR-129-5p alleviates myocardial injury by targeting suppressor of cytokine signaling 2 after ischemia/reperfusion[J]. Kaohsiung J Med Sci，2020，36（8）：599-606.
王留才，赵鹏，孙红蕾. 血清miR-129-5p水平与STEMI病人PCI术后预后的关系[J]. 中西医结合心脑血管病杂志，2022，20（8）：1488-1492.
WANG L C，ZHAO P，SUN H L. Relationship between serum miR-129-5p level and prognosis of STEMI patients after PCI[J]. Chin J Integr Med Cardio Cerebrovasc Dis，2022，20（8）：1488-1492.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.